L
Lumenis
Develops high quality medical devices for surgeries, aesthetics and opthalmology
About Lumenis
The story of Lumenis begins in the early 1990s with Dr. Shimon Eckhouse, who founded the company as ESC Medical Systems in Israel, focusing on intense pulsed light therapies. The company was an early pioneer in using light-based technology for aesthetic and medical treatments. It went public on the Nasdaq in 1996, and its valuation quickly grew. However, a subsequent acquisition of Laser Industries, a surgical laser company, proved challenging, leading to a period of struggle. The company, renamed Lumenis in 2001 , faced significant hurdles, including being delisted from the Nasdaq in 2006 amidst debt and accounting issues. A turning point came in 2012 with the appointment of Tzipi Ozer-Armon as CEO. Under her leadership, the company refocused and restructured. This new direction led to a successful re-listing on the Nasdaq in 2014. The next chapter saw a series of major acquisitions. In 2015, private equity fund XIO Group acquired Lumenis for approximately $520 million. This was followed in 2019 by another sale to Baring Private Equity Asia (BPEA) for over $1 billion. A significant strategic move occurred in 2021 when BPEA sold Lumenis' surgical division to Boston Scientific for $1.07 billion, while retaining the aesthetics and vision businesses. Today, Lumenis operates as a portfolio company of BPEA, continuing to develop and commercialize energy-based technologies for the global aesthetic and vision markets.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 1966
- Headquarters
- Yokneam Ilit, Israel
- Employees
- 1,414
- Open positions
- 36
- Dealroom signal
- 67.4/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Oncology, Ophthalmology, Skin Care, Surgery, Eye Diseases, Women's Health, Glaucoma, Laser Technology, Hospital
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2c
- Investment activity
- 1 company, latest Nov 2015
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| BUYOUT✓Exit | Nov 2019 | $1.2B | $1.2B | Baring Private Equity Partners | — |
| ACQUISITION✓Exit | Jun 2015 | $517M | $517M | XIO Group | ↗ |
Growth signals
Latest recorded traffic for Lumenis is 67K monthly website visits, up 81.1% over the last three months. Lumenis's team declined 1.4% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Viola Credit
XT Investments- OHOfer Hi-Tech
- AIAgate Medical Investments
Series B and later1 investor entered at this stage
Baring Private Equity Partners
Other known investors3 additional known investors
- XGXIO Group
Nir Dagan
The Knot Worldwide
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Lumenis on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Lumenis’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.